EMAIL THIS PAGE TO A FRIEND

Acta neuropathologica

Quantitative analysis and clinico-pathological correlations of different dipeptide repeat protein pathologies in C9ORF72 mutation carriers.


PMID 26374446

Abstract

Hexanucleotide repeat expansion in C9ORF72 is the most common genetic cause of frontotemporal dementia and motor neuron disease. One consequence of the mutation is the formation of different potentially toxic polypeptides composed of dipeptide repeats (DPR) (poly-GA, -GP, -GR, -PA, -PR) generated by repeat-associated non-ATG (RAN) translation. While previous studies focusing on poly-GA pathology have failed to detect any clinico-pathological correlations in C9ORF72 mutation cases, recent data from animal and cell culture models suggested that it may be only specific DPR species that are toxic and only when accumulated in certain intracellular compartments. Therefore, we performed a systematic clinico-pathological correlative analysis with counting of actual numbers of distinct types of inclusion (neuronal cytoplasmic and intranuclear inclusions, dystrophic neurites) for each DPR protein in relevant brain regions (premotor cortex, lower motor neurons) in a cohort of 35 C9ORF72 mutation cases covering the clinical spectrum from those with pure MND, mixed FTD/MND and pure FTD. While each DPR protein pathology had a similar pattern of anatomical distribution, the total amount of inclusions for each DPR protein varied remarkably (poly-GAxa0>xa0GPxa0>xa0GRxa0>xa0PR/PA), indicating that RAN translation seems to be more effective from sense than from antisense transcripts. Importantly, with the exception of moderate associations for the amount of poly-GA-positive dystrophic neurites with degeneration in the frontal cortex and total burden of poly-GA pathology with disease onset, no relationship was identified for any other DPR protein pathology with degeneration or phenotype. Biochemical analysis revealed a close correlation between insoluble DPR protein species and numbers of visible inclusions, while we did not find any evidence for the presence of soluble DPR protein species. Thus, overall our findings strongly argue against a role of DPR protein aggregation as major and exclusive pathomechanism in C9ORF72 pathogenesis. However, this does not exclude that DPR protein formation might be essential in C9ORF72 pathogenesis in interplay with other consequences associated with the C9ORF72 repeat expansion.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

SAB2701263
Anti-DCTN4 antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB2107220
Anti-DCTN4 antibody produced in rabbit, affinity isolated antibody
SAB2105017
Anti-DCTN4, (N-terminal) antibody produced in rabbit, affinity isolated antibody
GW22005A Anti-GTF2H1 (ab1) antibody produced in chicken, affinity isolated antibody, buffered aqueous solution
GW22005B Anti-GTF2H1 (ab2) antibody produced in chicken, affinity isolated antibody, buffered aqueous solution
AV100811
Anti-GTF2H1 antibody produced in rabbit, IgG fraction of antiserum
SAB2104463
Anti-GTF2H1 antibody produced in rabbit, affinity isolated antibody
GW22431A Anti-NUP62 antibody produced in chicken, affinity isolated antibody, buffered aqueous solution
HPA005435
Anti-NUP62 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB2101664
Anti-NUP62 antibody produced in rabbit, affinity isolated antibody
SAB1410438
Anti-NUP62 antibody produced in rabbit, purified immunoglobulin, buffered aqueous solution
SAB4200224
Anti-phospho-TDP-43 (pSer410) antibody produced in rabbit, ~1.0 mg/mL, affinity isolated antibody
SAB2102371
Anti-TARDBP (ab1) antibody produced in rabbit, affinity isolated antibody
AV38941
Anti-TARDBP (AB1) antibody produced in rabbit, IgG fraction of antiserum
SAB2102372
Anti-TARDBP (ab2) antibody produced in rabbit, affinity isolated antibody
AV38942
Anti-TARDBP (AB2) antibody produced in rabbit, IgG fraction of antiserum
SAB2501017
Anti-TARDBP antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB2701655
Anti-tardbp antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
HPA017284
Anti-TARDBP antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
T1580
Anti-TDP-43 (C-terminal) antibody produced in rabbit, ~1.0 mg/mL, affinity isolated antibody, buffered aqueous solution
T1705
Anti-TDP-43 antibody produced in rabbit, ~1.5 mg/mL, affinity isolated antibody, buffered aqueous solution
WH0002965M1
Monoclonal Anti-GTF2H1 antibody produced in mouse, clone 1F12-1B5, purified immunoglobulin, buffered aqueous solution
SAB1403894
Monoclonal Anti-GTF2H1, (C-terminal) antibody produced in mouse, clone 4B9, purified immunoglobulin, buffered aqueous solution
WH0023636M2
Monoclonal Anti-NUP62 antibody produced in mouse, clone 2D3, purified immunoglobulin, buffered aqueous solution
SAB1404985
Monoclonal Anti-NUP62 antibody produced in mouse, clone 1F12, purified immunoglobulin, buffered aqueous solution
WH0023435M1
Monoclonal Anti-TARDBP antibody produced in mouse, clone 2E2-D3, purified immunoglobulin, buffered aqueous solution
SAB1404973
Monoclonal Anti-TARDBP antibody produced in mouse, clone 1B4-B1, purified immunoglobulin, buffered aqueous solution